IMP3 and prostate cancer: Similarly, Ikenberg et al. [16] also found that IMP3 was significantly overexpressed in prostate carcinomas (from a total of 476 prostate cancer tissues which includes 425 primary carcinomas and 51 prostate cancer metastases or castration-resistant prostate cancers) as compared to the normal prostate tissues.